Navigation Links
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
Date:11/24/2008

el and selective adenosine2a receptor antagonist for Parkinson's disease (completing Phase II); results of a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson's disease were reported showing that preladenant met the primary endpoint.

Presenters reviewed a range of other therapies in various stages of development in the company's six therapeutic areas: allergy/respiratory; cardiovascular/metabolic; central nervous system; immunology/infectious disease; oncology; and women's health.

Several earlier-stage research projects were also unveiled for the first time, including:

  • Two monoclonal antibodies for oncology -- robatumumab (anti-IGF-1R) in Phase II and anti-HGF in Phase I;
  • Two projects for Alzheimer's -- a beta secretase inhibitor and a gamma secretase inhibitor; and
  • A novel anti-inflammatory agent, anti-IL-23, in Phase I for chronic inflammatory conditions.

In Animal Health, the company highlighted its global leadership position and diverse portfolio and pipeline, with more than 120 small-molecule projects and 140 biological projects under way. The company also highlighted three growth corridors for Schering-Plough: companion animal; parasiticides; and geographic expansion in the U.S., Japan and emerging markets.

Webcast Information

A replay of the webcast of Schering-Plough's "R&D Update" meeting is available by going to the Investor Relations section of the Schering-Plough corporate Web site, www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. The replay will be available starting on Nov. 24 through 5 p.m. on Dec. 24.

Disclosure Notice

DISCLOSURE NOTICE:
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
2. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
3. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
4. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
5. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
6. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
7. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
11. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... "Electrocardiogram (ECG) Devices - Global Trends, Estimates and ... http://photos.prnewswire.com/prnh/20130307/600769 Global Electrocardiogram ... by 2016. The North America ... share while Europe claims approximately ...
(Date:12/15/2014)... Norway , December 15, 2014 ... innovative drugs for aggressive drug resistant cancers, today announces ... in a private placing from new and existing investors. ... financing to support the development of its pipeline of ... program for its lead drug candidate, BGB324, a first-in-class ...
(Date:12/15/2014)... and BRIDGEWATER, N.J. , Dec. 15, ... Sanofi US (EURONEXT: SAN and NYSE: SNY) are collaborating ... launch Cholesterol Counts , an awareness program that ... numbers, and the risks associated with high LDL-C (bad ... CholesterolCounts .com to take a brief poll and ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
... uses quantitative imaging endpoints from MRI analysesROCHESTER, N.Y., ... VSCP ), a leading provider of quantitative imaging ... a Canadian medical device company based in Laval, ... Canadian-European pivotal clinical trial for its cartilage repair ...
... The following is being issued by Coast IRB: ... Coast IRB informed the public that it had discovered what ... Independent review board for evaluation. Coast IRB has since ... of a congressional "sting" operation. Apparently at the behest ...
Cached Medicine Technology:VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial 2VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial 3Congressional 'Sting' Operation Uncovered By Coast IRB 2
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a ... Future” and co-founder of the Ace Medical Weight Loss Center ... a broad look at the industry of weight loss, and ... On film and in television shows, however, she says the ... aspects and played for basic laughs, which she believes impacts ...
(Date:12/17/2014)... A group of 127 scientists sent an ... reaction to a recent statement by the center that was ... derogated the efficacy of all brain exercises. , Signatories to ... of the center’s statement critical of brain exercise companies that ... overstated its case, in a document it had entitled “A ...
(Date:12/17/2014)... December 17, 2014 Project Veritas is ... brought videos of MIT economist and Obamacare architect Jonathan ... James O’Keefe conducted the interview, which is being distributed ... there was intentional mislabeling in the Affordable Care Act ... bill: A two-hundred-and-fifty billion dollar per year tax grab. ...
(Date:12/17/2014)... TUESDAY, Dec. 16, 2014 (HealthDay News) -- Poor students get ... home, a new study finds. But, the opposite is ... that having fruits and vegetables at school may give a ... But, no matter what the family income level, students ... school, the study found. The study was published recently ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3
... Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare ... environmental and nutraceutical products, today announced that its monthly ... 2, 2009 at 4:30 PM Eastern Time. To ... 1-201-689-8471 (international). The call will also be webcast. ...
... athlete,s foot sufferers and parents.KENILWORTH, N.J., May 19 ... SGP ) today announced the arrival ... treatment of athlete,s foot. TINACTIN CHILL is available ... spray.(Photo: http://www.newscom.com/cgi-bin/prnh/20090519/NY19030 )To view the ...
... to profile "New Strategies for Optimizing CHO Performance" inside the BIO ... , ... Fort Collins, CO (PRWEB) May 19, 2009 -- ... 2009 International Convention will be InVitria, a cell culture media supplement ...
... by a Crohn,s patient with help from GI specialists, ... allows patients with (IBD) Crohn,s and Ulcerative Colitis to ... doctors.UPPER SADDLE RIVER, N.J., May 19 WellApps, Inc. ... Crohn,s and Ulcerative Colitis provide accurate symptom data to ...
... May 19 Regulatory processes differ across continents, ... pressing need to integrate the regulatory environment of ... regulations impact drug launches as less price controlled ... in regulated markets. The pharmaceutical industry, along with ...
... Gains Foothold in Healthcare with Launch Campaign for Bay ... ANGELES, May 19 Bob Gold & ... relations and marketing agency, announced today a new addition ... Group , a Torrance, Calif.-based practice that has ...
Cached Medicine News:Health News:Nuvilex, Inc. Announces Monthly Investor Conference Call 2Health News:Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males 2Health News:InVitria to Present at BIO 2009 International Convention in Atlanta 2Health News:IBD Patient Launches iPhone Application to Help Doctors Treat Crohn's and Ulcerative Colitis 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 3Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 4Health News:Bob Gold & Associates Steps Up as Marketing & PR Agency for Bay Harbor Podiatry Group 2
100L...
... pipette is ideal for repeated ... Fixed volume FInnpipettes offer the ... other Finnpipette Digital pipettes: ... (1-40ul), Soft-touch tip ejection, Safety ...
This fixed-volume digital micropipet is used to accurately measure and transfer 20 microliters of solution....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: